All lobbying filings

THE MCMANUS GROUP

Lobbying for ROCHE DIAGNOSTICS · Diagnostic test manufacturing

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

Indiana

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 5269
RESULTS Act
HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Lobbying activity 2

Medicare/Medicaid

H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Trade (domestic/foreign)

Issues related to global trade and tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.